Shruti Gupta, MD
Internal Medicine · Boston, MANPI 1619314853
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $16,460 of the $16,539 with a category attached, or 99.5%. 6 manufacturers reported payments, led by BTG International Inc. at 39.2% of the total. Among internal medicine clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 11 payments — averaging $1503.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- BTG International Inc.$6K
- GSK$6K
- Orion Corporation$3K
- EMD Serono Research & Development Institute, Inc.$950
- AstraZeneca$670
- Novartis$79
Across 22 payments — averaging $28,884 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- BTG International Inc.$587K
- AstraZeneca$48K
- GSK$1K
What the payments were for
- Consulting fees$16,460100%
- Food & beverage$790%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| BTG International Inc. | 3 | $6,490 |
| GSK | 3 | $5,750 |
| Orion Corporation | 2 | $2,600 |
| EMD Serono Research & Development Institute, Inc. | 1 | $950 |
| AstraZeneca | 1 | $670 |
| Novartis | 1 | $79 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VORAXAZE$6,490
How this compares
$16,539 in reported general payments places this provider in the 95th percentile of 4,983 internal medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 30 | $18,917 |
| Carvedilol | 29 | $280 |
| Amlodipine Besylate | 32 | $230 |
| Famotidine | 29 | $169 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 17 | $115 |
| Lisinopril | 18 | $103 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Boston
- David SchenkeinBoston$5M
- John FallonBoston$1.8M
- Michael MendelsohnBoston$1.6M
- Gaurav SingalBoston$798K
- Asit ParikhBoston$486K
- Noopur RajeBoston$481K
- Daniel KuritzkesBoston$443K
- Xiuning leBoston$364K
- Nancy GaglianoBoston$358K
- Fatima StanfordBoston$285K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.